Search CDMOs

Advanced therapies CDMO providing discovery, process development, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA, and gene editing programs from preclinical through commercial scale.

Integrated CRDMO offering discovery, development, and manufacturing services for small molecule NCE programs across 280+ global pharma and biotech clients.

Metrics Contract Services, acquired by Catalent in 2024 for $475 million, operates a state-of-the-art facility in Greenville, North Carolina specializing in oral solid formulation development, manufacturing, and packaging. The organization brings over 20 years of experience…

Specialized global CDMO for peptide-based active pharmaceutical ingredients, supporting development and manufacturing of proprietary and generic APIs with expertise in peptide synthesis and GMP manufacturing.

Global CDMO with 7,900+ employees across 18 facilities, offering integrated drug development and manufacturing services including analytical development, formulation, process development, fill-finish, and specialized chemistry capabilities.

Global CDMO with 16 production sites across four continents, offering integrated development and manufacturing from early-phase to commercial scale for drug substance and drug product.

Global CDMO partner offering 360° integrated drug development solutions from early-stage R&D through clinical supply and commercial manufacturing for biologics and small molecules.

CDMO and CRO offering downstream processing, protein purification, and manufacturing capabilities for therapeutic antibodies and biologics from discovery through commercialization.

VVector Bio is a spin-out of McGill University developing cutting-edge technologies for cost-effective manufacturing of cell and gene therapies. The company specializes in advanced plasmid and cell systems leveraging functional genomics to improve AAV yields and quality by…

Esco Aster is a vertically integrated CDMO and CRO delivering end-to-end contract solutions from process development and GMP manufacturing through clinical research, with specialized capabilities in vaccine production, cell therapy, plasmid DNA, extracellular vesicles, and GLP toxicology.

Leading global provider of integrated drug containment, drug delivery, and diagnostic solutions with 75+ years' experience in glass primary packaging, contract manufacturing, and analytical services across development, clinical, and commercial stages.

U.S. pharmaceutical CDMO offering design, development, and manufacturing from early formulation to commercial-scale production, with cGMP capabilities including spray drying, particle engineering, and complex oral dosage forms.

Sterile injectable CDMO specializing in formulation development, lyophilization, fill/finish, and ADC manufacturing with cGMP-compliant facilities in the U.S. and Germany.

Leading public health company specializing in medical countermeasures, commercial products, and strategic manufacturing partnerships for biodefense and public health preparedness.

Global pharmaceutical manufacturer with robust quality systems aligned to US FDA, UK MHRA, and EU GMP standards; operates diversified manufacturing across generics, complex formulations, and specialty segments with advanced automation and digital quality infrastructure.

JRS Pharma provides innovative excipients, coatings, formulation expertise, and biopharma services for solid and liquid dosage form development and manufacturing.

CDMO specializing in cytotoxic and high-potency oncology drugs, ADCs, peptides, proteins, oligonucleotides, and lipid-based formulations with GLP development through cGMP commercial manufacturing across segregated high-containment facilities.

Global CDMO offering cell line development, process development, analytical services, and cGMP clinical and commercial manufacturing for biologics including monoclonal antibodies and recombinant proteins.

Global CDMO with 30+ years of experience offering integrated services across small molecule, generic APIs, sterile drug product, and biologics manufacturing, backed by 20+ facilities and 3,000+ professionals across North America, Europe, and India.

End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.